These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 31402562)

  • 21. Everolimus plus exemestane versus bevacizumab-based chemotherapy for second-line treatment of hormone receptor-positive metastatic breast cancer in Greece: An economic evaluation study.
    Kourlaba G; Rapti V; Alexopoulos A; Relakis J; Koumakis G; Chatzikou M; Maniadakis N; Georgoulias V
    BMC Health Serv Res; 2015 Aug; 15():307. PubMed ID: 26239115
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial.
    Kimbung S; Markholm I; Bjöhle J; Lekberg T; von Wachenfeldt A; Azavedo E; Saracco A; Hellström M; Veerla S; Paquet E; Bendahl PO; Fernö M; Bergh J; Loman N; Hatschek T; Hedenfalk I;
    Int J Cancer; 2018 Feb; 142(3):618-628. PubMed ID: 28940389
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Integrated analysis of mRNA and miRNA profiles revealed the role of miR-193 and miR-210 as potential regulatory biomarkers in different molecular subtypes of breast cancer.
    Evangelista AF; Oliveira RJ; O Silva VA; D C Vieira RA; Reis RM; C Marques MM
    BMC Cancer; 2021 Jan; 21(1):76. PubMed ID: 33461524
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dynamics of circulating microRNAs as a novel indicator of clinical response to neoadjuvant chemotherapy in breast cancer.
    Zhu W; Liu M; Fan Y; Ma F; Xu N; Xu B
    Cancer Med; 2018 Sep; 7(9):4420-4433. PubMed ID: 30099860
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Widespread estrogen-dependent repression of micrornas involved in breast tumor cell growth.
    Maillot G; Lacroix-Triki M; Pierredon S; Gratadou L; Schmidt S; Bénès V; Roché H; Dalenc F; Auboeuf D; Millevoi S; Vagner S
    Cancer Res; 2009 Nov; 69(21):8332-40. PubMed ID: 19826037
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bevacizumab in the neoadjuvant treatment of human epidermal growth factor receptor 2-negative breast cancer: A meta-analysis of randomized controlled trials.
    Nahleh Z; Botrus G; Dwivedi A; Jennings M; Nagy S; Tfayli A
    Mol Clin Oncol; 2019 Mar; 10(3):357-365. PubMed ID: 30847174
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The efficacy and safety of bevacizumab combined with chemotherapy in treatment of HER2-negative metastatic breast cancer: a meta-analysis based on published phase III trials.
    Fang Y; Qu X; Cheng B; Chen Y; Wang Z; Chen F; Xiong B
    Tumour Biol; 2015 Mar; 36(3):1933-41. PubMed ID: 25387808
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Efficacy of neoadjuvant chemotherapy combined with bevacizumab versus neoadjuvant chemotherapy alone for Her2-negative breast cancer: a meta-analysis of randomized controlled clinical trials].
    Han R; Wang G; Zhang Y; Zhao X
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2016 May; 45(4):379-386. PubMed ID: 27868411
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neoadjuvant bevacizumab: surgical complications of mastectomy with and without reconstruction.
    Kansal KJ; Dominici LS; Tolaney SM; Isakoff SJ; Smith BL; Jiang W; Brock JE; Winer EP; Krop IE; Golshan M
    Breast Cancer Res Treat; 2013 Sep; 141(2):255-9. PubMed ID: 24026859
    [TBL] [Abstract][Full Text] [Related]  

  • 30. miRNA-205 targets VEGFA and FGF2 and regulates resistance to chemotherapeutics in breast cancer.
    Hu Y; Qiu Y; Yagüe E; Ji W; Liu J; Zhang J
    Cell Death Dis; 2016 Jun; 7(6):e2291. PubMed ID: 27362808
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study.
    Bertucci F; Fekih M; Autret A; Petit T; Dalenc F; Levy C; Romieu G; Bonneterre J; Ferrero JM; Kerbrat P; Soulie P; Mouret-Reynier MA; Bachelot T; Lerebours F; Eymard JC; Deblock M; Lortholary A; Hardy-Bessard AC; Barthelemy P; Bonnefoi H; Charafe-Jauffret E; Bidard FC; Viens P; Lemonnier J; Pierga JY
    Lancet Oncol; 2016 May; 17(5):600-11. PubMed ID: 27032301
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial†.
    Pujol JL; Lavole A; Quoix E; Molinier O; Souquet PJ; Barlesi F; Le Caer H; Moro-Sibilot D; Fournel P; Oster JP; Chatellain P; Barre P; Jeannin G; Mourlanette P; Derollez M; Herman D; Renault A; Dayen C; Lamy PJ; Langlais A; Morin F; Zalcman G;
    Ann Oncol; 2015 May; 26(5):908-914. PubMed ID: 25688059
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial.
    Balana C; De Las Penas R; Sepúlveda JM; Gil-Gil MJ; Luque R; Gallego O; Carrato C; Sanz C; Reynes G; Herrero A; Ramirez JL; Pérez-Segura P; Berrocal A; Vieitez JM; Garcia A; Vazquez-Estevez S; Peralta S; Fernandez I; Henriquez I; Martinez-Garcia M; De la Cruz JJ; Capellades J; Giner P; Villà S
    J Neurooncol; 2016 May; 127(3):569-79. PubMed ID: 26847813
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer.
    Clavarezza M; Turazza M; Aitini E; Saracchini S; Garrone O; Durando A; De Placido S; Bisagni G; Levaggi A; Bighin C; Restuccia E; Scalamogna R; Galli A; Del Mastro L
    Breast; 2013 Aug; 22(4):470-5. PubMed ID: 23642526
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Global microRNA expression profiling identifies MiR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancer.
    Rothé F; Ignatiadis M; Chaboteaux C; Haibe-Kains B; Kheddoumi N; Majjaj S; Badran B; Fayyad-Kazan H; Desmedt C; Harris AL; Piccart M; Sotiriou C
    PLoS One; 2011; 6(6):e20980. PubMed ID: 21738599
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of high-grade serous ovarian cancer miRNA species associated with survival and drug response in patients receiving neoadjuvant chemotherapy: a retrospective longitudinal analysis using matched tumor biopsies.
    Petrillo M; Zannoni GF; Beltrame L; Martinelli E; DiFeo A; Paracchini L; Craparotta I; Mannarino L; Vizzielli G; Scambia G; D'Incalci M; Romualdi C; Marchini S
    Ann Oncol; 2016 Apr; 27(4):625-34. PubMed ID: 26782955
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40.
    Bear HD; Tang G; Rastogi P; Geyer CE; Zoon CK; Kidwell KM; Robidoux A; Baez-Diaz L; Brufsky AM; Mehta RS; Fehrenbacher L; Young JA; Senecal FM; Gaur R; Margolese RG; Adams PT; Gross HM; Costantino JP; Paik S; Swain SM; Mamounas EP; Wolmark N
    Ann Surg Oncol; 2017 Jul; 24(7):1853-1860. PubMed ID: 27864694
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†.
    von Minckwitz G; Loibl S; Untch M; Eidtmann H; Rezai M; Fasching PA; Tesch H; Eggemann H; Schrader I; Kittel K; Hanusch C; Huober J; Solbach C; Jackisch C; Kunz G; Blohmer JU; Hauschild M; Fehm T; Nekljudova V; Gerber B; ; Gnauert K; Heinrich B; Prätz T; Groh U; Tanzer H; Villena C; Tulusan A; Liedtke B; Blohmer JU; Kittel K; Mau C; Potenberg J; Schilling J; Just M; Weiss E; Bückner U; Wolfgarten M; Lorenz R; Doering G; Feidicker S; Krabisch P; Deichert U; Augustin D; Kunz G; Kast K; von Minckwitz G; Nestle-Krämling C; Rezai M; Höß C; Terhaag J; Fasching P; Staib P; Aktas B; Kühn T; Khandan F; Möbus V; Solbach C; Tesch H; Stickeler E; Heinrich G; Wagner H; Abdallah A; Dewitz T; Emons G; Belau A; Rethwisch V; Lantzsch T; Thomssen C; Mattner U; Nugent A; Müller V; Noesselt T; Holms F; Müller T; Deuker JU; Schrader I; Strumberg D; Uleer C; Solomayer E; Runnebaum I; Link H; Tomé O; Ulmer HU; Conrad B; Feisel-Schwickardi G; Eidtmann H; Schumacher C; Steinmetz T; Bauerfeind I; Kremers S; Langanke D; Kullmer U; Ober A; Fischer D; Kohls A; Weikel W; Bischoff J; Freese K; Schmidt M; Wiest W; Sütterlin M; Dietrich M; Grießhammer M; Burgmann DM; Hanusch C; Rack B; Salat C; Sattler D; Tio J; von Abel E; Christensen B; Burkamp U; Köhne CH; Meinerz W; Graßhoff ST; Decker T; Overkamp F; Thalmann I; Sallmann A; Beck T; Reimer T; Bartzke G; Deryal M; Weigel M; Huober J; Weder P; Steffens CC; Lemster S; Stefek A; Ruhland F; Hofmann M; Schuster J; Simon W; Kronawitter U; Clemens M; Fehm T; Janni W; Latos K; Bauer W; Roßmann A; Bauer L; Lampe D; Heyl V; Hoffmann G; Lorenz-Salehi F; Hackmann J; Schlag R
    Ann Oncol; 2014 Dec; 25(12):2363-2372. PubMed ID: 25223482
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum microRNA-195 is down-regulated in breast cancer: a potential marker for the diagnosis of breast cancer.
    Zhao FL; Dou YC; Wang XF; Han DC; Lv ZG; Ge SL; Zhang YK
    Mol Biol Rep; 2014 Sep; 41(9):5913-22. PubMed ID: 25103018
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Noninvasive Characterization of Tumor Angiogenesis and Oxygenation in Bevacizumab-treated Recurrent Glioblastoma by Using Dynamic Susceptibility MRI: Secondary Analysis of the European Organization for Research and Treatment of Cancer 26101 Trial.
    Kickingereder P; Brugnara G; Hansen MB; Nowosielski M; Pflüger I; Schell M; Isensee F; Foltyn M; Neuberger U; Kessler T; Sahm F; Wick A; Heiland S; Weller M; Platten M; von Deimling A; Maier-Hein KH; Østergaard L; van den Bent MJ; Gorlia T; Wick W; Bendszus M
    Radiology; 2020 Oct; 297(1):164-175. PubMed ID: 32720870
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.